Our Current Partners

The PREVENT partnership is led by an extensive body of expertise including a team of over fifty internationally recognized authorities on infectious diseases from:
Our Founding Partners:

VIDO-InterVacVaccine and Infectious Disease Organization (VIDO-InterVac)

(Saskatoon, Saskatchewan): The internationally recognized organization provides for a preclinical research capacity (Containment Level 2 laboratory and animal facilities) for immunogenicity and animal-model disease studies within the PREVENT effort. The International Vaccine Centre (InterVac), is Canada’s largest Level 3 Containment laboratory dedicated to vaccine development, and it has the capacity to test vaccines in large animals challenged with biosafety level 3 pathogens. Dr. Andy Potter is the Chief Executive Officer of VIDO-InterVac.

The Canadian Center for Vaccinology

The Canadian Center for Vaccinology (CCfV) (Halifax, Nova Scotia): A partnership among Dalhousie University, the IWK Health Centre and Capital Health houses a 30,000 square foot vaccine research centre for clinical trials (Phase I-III). Research is undertaken here at both basic and translational science levels. The CCfV focuses on epidemiology, implementation and evaluative policy research. Dr. Scott Halperin is the Executive Director of the CCfV.

The British Columbia Centre for Disease Control

The British Columbia Centre for Disease Control (BCCDC) (Vancouver, British Columbia): The BCCDC undertakes and evaluates discovery research for the PREVENT effort. The BCCDC is a provincial and national leader in public health through surveillance, detection, treatment, and prevention and consultation services. The Centre provides leadership on immunization practices for the province and provides analytical and public support to government and health authorities. Dr. Robert Brunham is the Executive Director of the BCCDC and a professor of Medicine, UBC.

Our Funders:

The Networks of Centres of Excellence of CanadaThe Networks of Centres of Excellence of Canada, a joint initiative of the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council, the Canadian Institutes of Health Research, Industry Canada and Health Canada.

Our Commercial Partners :


Amorfix: PREVENT, UBC and Amorfix are collaborating to develop a vaccine for amyotrophic lateral sclerosis (ALS, Lou Gehrig disease). Amorfix Life Sciences Ltd is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including BSE, ALS, cancer, and Alzheimer’s Disease.

British Columbia Centre for Disease Control (BCCDC): PREVENT, UBC, and the BCCDC are collaborating to develop a vaccine targeting Chlamydia trachomatis. The BCCDC provides provincial and national leadership in public health through surveillance, detection, treatment, prevention and consultation services. The Centre provides both direct diagnostic and treatment services for people with diseases of public health importance and analytical and policy support to all levels of government and health authorities.

Folia BiotechFolia Biotech: PREVENT and Folia Biotech are collaborating to develop an influenza vaccine combined with a novel adjuvant designed to enhance the immune response. Folia Biotech is a Canadian biotechnology company whose core technology is vaccine enhancement through a remarkable new adjuvant derived from the coat protein of the papaya mosaic virus (PapMV).

VIDO-InterVac: PREVENT and VIDO-InterVac are collaborating to develop a vaccine that combines the respiratory syncytial virus (RSV) F-protein immunogen with a patented defined novel adjuvant. VIDO is a non-profit research organization owned by the University of Saskatchewan, and is focused on investigating the pathogenesis of infectious diseases and the development of effective therapeutic and prophylactic methods to control infectious diseases of humans and animals.

UBC The University of British Columbia (UBC): PREVENT, the Brain Research Centre at UBC, and VIDO are collaborating to develop a vaccine for misfolded prion proteins. The UBC was established in 1908, is one of Canada’s leading research universities and is consistently ranked among the top 40 in the world. The Brain Research Centre, located in Vancouver, Canada, is a unique partnership between Vancouver Coastal Health Research Institute and the Faculty of Medicine at the University of British Columbia. The hospital has combined forces with broad, multi- disciplinary research expertise at the University of British Columbia to advance knowledge of the brain and to explore new discoveries and technologies that have the potential to reduce the suffering and cost associated with disease and injuries of the brain.

Vaxent Inc.Vaxent Inc.: PREVENT and Vaxent are collaborating in the development of a 30-valent vaccine for group A streptococcus (GAS). Vaxent is an early stage vaccine development company located in Memphis, Tennessee, whose lead product in development is a subunit vaccine against group A streptococcus (GAS), earlier versions of which have been tested in early stage human clinical trials with no adverse events.

Continue Reading

Become a Partner

PREVENT targets new vaccines, improved vaccine formulations, and delivery strategies developed at Canadian universities, research institutions, university spin-offs, biotech companies, and other sources. By partnering with PREVENT you gain access to:

  • Risk Mitigation: PREVENT identifies successful vaccine candidates and develops them to a stage where significant commercial value has been added to these technologies and risk has been adequately diminished to encourage subsequent commercialization activities.
  • Expertise: PREVENT works with industry partners to develop vaccine candidates for the marketplace, with the technologies transferred to receptor organizations either in the private or public sector.
  • An Accelerated Market Pathway: PREVENT assists in fast-tracking zoonotic veterinary and human vaccine development for diseases of major public health concern, and navigates a pathway to commercialization that promotes growth, investment, and improved global competitiveness for Canada’s vaccine industry.
  • Resources: PREVENT provides financial and directs technical advancements for post-proof-of-principle vaccine candidates that have at minimum demonstrated efficacy in a relevant animal model, and which also hold promise for managing serious disease issues.
Continue Reading